Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's Major Generics Drug Maker Sawai Pharmaceutical Looks To M&A For Growth

This article was originally published in PharmAsia News

Executive Summary

In an interview with Reuters, Japan's major generic drug maker Sawai Pharmaceutical President Mitsuo Sawai disclosed a goal of doubling sales in five years to become a ¥100 billion company by 2014. Sawai explained that the scale will allow the company to fully utilize its specialty in generics business. To achieve the goal, enriching product lineup and expanding business scale through mergers and acquisitions are necessary, Sawai stated. He further set eye care and tropical products as candidates for partnership. Regarding Daiichi Sankyo's entry to the generics market through buying Indian firm Ranbaxy, Sawai estimated that the joint Daiichi Sankyo-Ranbaxy will first focus on expanding markets in developing countries. He also doubted that Daiichi Sankyo would focus on generics business. As a new drug discovery company, promoting generic versions of its own brand products is equal to wrapping a rope around the neck, Sawai added. (Click here for more - Japanese language) "Sawai Pharmaceutical President-M&A Necessary To Grow Sales To 100 Billion" - Reuters Japan (8/28/08)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts